Eurofarma Biosimilars Deal Broadens Access To Latin America For Henlius
Chinese Firm’s Bevacizumab, Rituximab And Trastuzumab Included In $50m Deal
Shanghai Henlius Biotech has announced a licensing deal for three biosimilars – bevacizumab, rituximab and trastuzumab – with Brazil’s Eurofarma. The agreement, which could be worth as much as $50.5m, gives the Chinese company enhanced access to Latin America as it continues to broaden its global footprint.
